On Oct 9, 2020, the US Food and Drug Administration (FDA) issued a warning on the lamotrigine datasheet including this statement: "avoid LAMICTAL (ie, lamotrigine) in patients with certain underlying cardiac disorders or arrhythmias".1 According to the update, the drug might have class Ib antiarrhythmic activity at therapeutically relevant concentrations. This effect could result in a widening of the QRS complex, induce new cardiac arrhythmias, and lead to sudden death. The warning also stated that lamotrigine should be avoided in individuals with cardiac conduction abnormalities, ventricular arrhythmias, or structural heart disease.
展开▼
